Trisomy 12 and K-ras-2 amplification in human ovarian tumors.
Cytogenetic analysis was performed on 11 benign and borderline ovarian tumors. Trisomy 12, identified as a sole abnormality in 6 tumors, is likely a specific karyotypic change in different benign and borderline tumors and may well be a primary chromosomal lesion in these tumors. The possible association between amplification of the proto-oncogene K-ras-2 which is located on chromosome 12 and trisomy 12 was investigated. DNA blotting analysis of 64 tumors indicates that trisomy 12 does not seem to be related to K-ras-2 amplification in ovarian tumors. K-ras-2 amplification was observed in 3 high-grade tumors from 3 patients with metastases.
Yang-Feng
T L
TL
Department of Human Genetics, Yale University School of Medicine, New Haven, CT 06510-8005.
Li
S B
SB
Leung
W Y
WY
Carcangiu
M L
ML
Schwartz
P E
PE
D002871:Chromosome Banding; D002881:Chromosomes, Human, Pair 12; D003537:Cystadenoma / Q000235:genetics / Q000473:pathology; D005260:Female; D005350:Fibroma / Q000235:genetics / Q000473:pathology; D005784:Gene Amplification; D011905:Genes, ras; D006801:Humans; D007621:Karyotyping; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D010212:Papilloma / Q000235:genetics / Q000473:pathology; D000090063:Proto-Oncogene Mas; D014314:Trisomy